Rivastigmine Tartrate Capsule
Product Images NDC 55111-352

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 55111-352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container2 (Container2)

Rivastigmine Tartrate Capsules, USP 3 mg, oral capsules in a bottle label format. The label states Rx Only and contains 60 capsules. It is manufactured by Dr. Reddy's Laboratories Limited. The label includes dosage instructions, storage conditions, and a barcode.*

FDA Label Image

Container3 (Container3)

Label for Rivastigmine Tartrate Capsules, USP 4.5 mg by Dr. Reddy's Laboratories Limited. The label indicates the product contains 60 capsules and is Rx only. It includes storage instructions, a barcode, and the NDC 55111-354-60.*

FDA Label Image

Container4 (Container4)

Label for Rivastigmine Tartrate Capsules USP, 6 mg strength, oral dosage form. The label indicates a package of 60 capsules and is marked for prescription use only (Rx only). The product is labeled by Dr. Reddy's Laboratories Limited, India. The label includes storage instructions and a barcode.*

FDA Label Image

Container1 (Contianer1)

Label for Rivastigmine Tartrate Capsules, USP 1.5 mg by Dr. Reddy's Laboratories Limited. The label states prescription use, contains 60 capsules, and includes NDC 55111-352-60. It displays dosage strength prominently in orange with storage and packaging details, barcode, and manufacturer information on the right side.*

FDA Label Image

Fig1 (Fig1)

A line graph showing mean change from baseline ADAS-cog rating over 26 weeks during treatment for three groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents weeks of treatment, and the y-axis represents mean change, with clinical improvement indicated above zero and clinical decline below zero. Error bars represent SEM.*

FDA Label Image

Fig2 (Fig2)

A cumulative percentage graph showing change from baseline in ADAS-cog scores among patients treated with Rivastigmine Tartrate at doses of 1-4 mg/day and 6-12 mg/day, compared to placebo. The x-axis represents change from baseline, the y-axis shows cumulative percentage of patients, with annotations indicating levels of change and a table summarizing mean change values for each treatment group.*

FDA Label Image

Fig3 (Fig3)

A bar chart displaying the percentage of patients categorized by CIBIC-Plus ratings, comparing Placebo, 1-4 mg, and 6-12 mg groups. The ratings include Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse, showing distribution differences across the three groups.*

FDA Label Image

Fig4 (Fig4)

A line graph depicting mean change from baseline ADAS-cog total score over 26 weeks of treatment. It compares three groups: 6-12 mg, 1-4 mg, and placebo. The vertical scale ranges from clinical improvement to clinical decline, showing that higher dose groups tend toward clinical improvement, while placebo trends toward decline.*

FDA Label Image

Fig5 (Fig5)

A cumulative percentage plot showing change from baseline in ADAS-cog scores for three groups: placebo, 1-4 mg/day, and 6-12 mg/day Rivastigmine Tartrate. The X-axis represents change from baseline, the Y-axis cumulative percentage of patients, with vertical lines indicating -7 points, -4 points, and no change. A table inset compares treatment groups and placebo for these changes.*

FDA Label Image

Fig6 (Fig6)

A bar chart displaying patient distribution by CIBIC-Plus rating categories. The x-axis shows ratings from 'Markedly Improved' to 'Markedly Worse,' and the y-axis indicates percentage of patients. Three groups are compared: Placebo, 1-4 mg, and 6-12 mg doses, illustrating patient response variations across treatment groups.*

FDA Label Image

Fig7 (Fig7)

A line graph illustrating mean change from baseline ADAS-Cog total score during 24 weeks of treatment comparing Rivastigmine Tartrate and placebo. The y-axis represents cognitive change from clinical decline to improvement, and the x-axis shows weeks during treatment. Rivastigmine Tartrate shows greater clinical improvement over placebo by week 24.*

FDA Label Image

Fig8 (Fig8)

Bar chart comparing percentages of patients by ADCS-CGIC Rating for rivastigmine tartrate versus placebo groups. Categories include Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse, with varying percentages shown for each group.*

FDA Label Image

Structure (Structure)

Chemical structure of Rivastigmine Tartrate shown in a molecular diagram, including detailed atomic connectivity and functional groups, with notation indicating the tartrate moiety (C4H6O6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.